BioCentury | Mar 29, 2019
Preclinical News

NCI team details method to improve T cell therapies

Nicholas Restifo; acetyl-coenzyme A (acetyl CoA); acyl-CoA synthetase short-chain family member 1 (ACSS1) A team led by NCI's Nicholas Restifo showed raising potassium levels or adding a citrate derivative when manufacturing adoptive T cell therapies...
BioCentury | Feb 15, 2017
Distillery Therapeutics

Infectious disease

INDICATION: Cytomegalovirus (CMV) Cell culture studies suggest inhibiting ACSS2 could help treat CMV infection. In two human foreskin fibroblast cell lines infected with human CMV, ACSS2 knockout decreased viral titers compared with normal ACSS2 expression....
BioCentury | Jan 27, 2017
Targets & Mechanisms

Death metal

The findings in two high profile papers on ferroptosis could be the nudge the fledgling field needs to gain the attention of drug developers. The process is the latest cell death pathway to offer up...
BioCentury | Jan 25, 2017
Distillery Therapeutics

Renal disease

INDICATION: Renal failure Mouse studies suggest inhibiting ACSL4 could help treat acute renal failure. In a mouse embryonic fibroblast-based assay of ferroptosis, a regulated cell death mechanism associated with acute renal failure, ACSL4 knockout increased...
BioCentury | Jun 23, 2016
Distillery Techniques

Techniques: Structural analyses of polycomb repressive complex 2 (PRC2) bound to an inhibitor and a mutant histone H3 substrate

Drug platforms TECHNOLOGY: Structural analyses Structural analyses of PRC2 bound to an inhibitor or histone H3 substrate could help guide the development of PRC2 inhibitors for cancer that bypass known mechanisms of resistance. Analysis of...
BioCentury | Mar 12, 2015
Distillery Therapeutics

Therapeutics: Acyl-CoA synthetase short-chain family member 2 (ACSS2)

Cancer INDICATION: Cancer Studies in cell culture, mice and patient samples suggest inhibiting ACSS2 could help treat cancer. ACSS2 converts acetate to acetyl-CoA as part of the Krebs cycle, which oxidizes acetate to produce energy....
BioCentury | Feb 5, 2015
Distillery Therapeutics

Therapeutics: Acyl-CoA synthetase short-chain family member 2 (ACSS2)

Cancer INDICATION: Cancer Mouse and patient studies suggest inhibiting ACSS2 could help treat cancer. In patient breast tumor samples, elevated ACSS2 levels were associated with advanced tumor stage and poor survival. In mouse xenograft models...
BioCentury | Sep 18, 2014
Distillery Therapeutics

Indication: Hematology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Hematology Anemia Acyl-CoA synthetase short-chain family member 2 (ACSS2); endothelial PAS domain protein 1 (EPAS1; HIF2A); erythropoietin (EPO) Mouse studies suggest acetate supplementation could help treat...
BioCentury | Jul 24, 2014
Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease HCV Acyl-CoA synthetase long-chain family member 1 (ACSL1) Cell culture studies suggest inhibiting synthesis of triacylglycerides and cholesterol esters by ACSL1 could help treat...
BioCentury | Jan 26, 2012
Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Atherosclerosis Acyl-CoA synthetase long-chain family member 1 (ACSL1) Studies in mice and in patient samples suggest inhibiting ACSL1 could help...
Items per page:
1 - 10 of 10